Impact of improved classification on the association of human papillomavirus with cervical precancer

American Journal of Epidemiology

Volumn 171, Issue 2, 2010, Pages 155-163

  Castle, Philip E ^a   Schiffman, Mark ^a   Wheeler, Cosette M ^b   Wentzensen, Nicolas ^a   Gravitt, Patti E ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cervical intraepithelial neoplasia; Misclassification; Papillomavirus infections; Uterine cervical neoplasms

Indexed keywords

CANCER; EPIDEMIOLOGY; LESION; VIRAL DISEASE; WOMENS HEALTH;

ADULT; ARTICLE; CANCER CLASSIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRECANCER; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 73949103707     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwp390     Document Type: Article

References (51)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human pap-illomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19.
2. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-527. (Pubitemid 36159887)
3. Wright TC Jr, Schiffman M. Adding a test for human papil-lomavirus DNA to cervical-cancer screening. N Engl J Med. 2003;348(6):489-490.
4. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
5. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9(5):425-434.
6. Green GH. The progression of pre-invasive lesions of the cervix to invasion. N Z Med J. 1974;80(525):279-287.
7. Castle PE, Cox JT, Jeronimo J, et al. An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). Obstet Gynecol. 2008; 111(4):847-856.
8. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001; 285(11):1500-1505.
9. Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007;11(4): 201-222.
10. Castle PE, Stoler MH, Solomon D, et al. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol. 2007;127(5): 805-815.
11. Castle PE, Schiffman M, Wheeler CM, et al. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113(1):18-25.
12. Trimble CL, Piantadosi S, Gravitt P, et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res. 2005;11(13):4717-4723.
13. Carreon JD, Sherman ME, Guillén D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007;26(4):441-446.
14. Franco EL. The sexually transmitted disease model for cervical cancer: incoherent epidemiologic findings and the role of misclassification of human papillomavirus infection. Epidemiology. 1991;2(2):98-106.
15. Franco EL. Measurement errors in epidemiological studies of human papillomavirus and cervical cancer. IARC Sci Publ. 1992;119:181-197.
16. Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst. 1999;91(6):506-511.
17. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993; 85(12):958-964.
18. Kurman RJ, Malkasian GD Jr, Sedlis A, et al. From Papani-colaou to Bethesda: the rationale for a new cervical cytologic classification. Obstet Gynecol. 1991;77(5):779-782.
19. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114-2119.
20. Schiffman M, Adrianza ME. ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol. 2000;44(5):726-742.
21. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. J Natl Cancer Inst. 2000;92(5):397-402.
22. ASCUS-LSILTriage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003; 188(6):1393-1400.
23. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188(6):1383-1392.
24. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93(4):293-299. (Pubitemid 32219816)
25. Schiffman M, Wheeler CM, Dasgupta A, et al. A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal Papanicolaou smears. Am J Clin Pathol. 2005;124(5):722-732.
26. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000; 38(1):357-361.
27. Peyton CL, Gravitt PE, Hunt WC, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis. 2001;183(11):1554- 1564.
28. Castle PE, Gravitt PE, Solomon D, et al. Comparison of linear array and line blot assay for detection of human papilloma-virus and diagnosis of cervical precancer and cancer in the Atypical Squamous Cell of Undetermined Significance and Low-Grade Squamous Intraepithelial Lesion Triage Study. J Clin Microbiol. 2008;46(1):109-117.
29. Wentzensen N, Gravitt PE, Solomon D, et al. A study of Amplicor human papillomavirus DNA detection in the Atypical Squamous Cells of Undetermined Significance-Low-Grade Squamous Intraepithelial Lesion Triage Study. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1341-1349.
30. Bosch FX, Manos MM, Muñoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87(11):796-802.
31. Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6(4):204.
32. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol. 2009; 10(4):321-322.
33. Castle PE, Solomon D, Wheeler CM, et al. Human papillo-mavirus genotype specificity of hybrid capture 2. J Clin Microbiol. 2008;46(8):2595-2604.
34. Pretorius RG, Zhang WH, Belinson JL, et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol. 2004;191(2):430-434.
35. Gage JC, Hanson VW, Abbey K, et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol. 2006; 108(2):264-272.
36. Guido R, Schiffman M, Solomon D, et al. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol. 2003;188(6):1401-1405.
37. Atkins KA, Jeronimo J, Stoler MH. Description of patients with squamous cell carcinoma in the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intrae-pithelial Lesion Triage Study. Cancer. 2006;108(4):212-221.
38. Cuzick J. A Wilcoxon-type test for trend. Stat Med. 1985;4(1): 87-90.
39. Gravitt PE, Burk RD, Lorincz A, et al. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev. 2003;12(6):477-484.
40. Schiffman MH, Schatzkin A. Test reliability is critically important to molecular epidemiology: an example from studies of human papillomavirus infection and cervical neoplasia. Cancer Res. 1994;54(7 suppl):1944s-1947s.
41. Schatzkin A, Freedman LS, Dorgan J, et al. Surrogate end points in cancer research: a critique. Cancer Epidemiol Bio-markers Prev. 1996;5(12):947-953.
42. Reeves WC, Brinton LA, Garćia M, et al. Human papilloma-virus infection and cervical cancer in Latin America. N Engl J Med. 1989;320(22):1437-1441. (Pubitemid 19143707)
43. Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244-265. (Pubitemid 34293391)
44. Schiffman M, Rodriguez AC. Heterogeneity in CIN3 diagnosis. Lancet Oncol. 2008;9(5):404-406.
45. Sherman ME, Wang SS, Tarone R, et al. Histopathologic extent of cervical intraepithelial neoplasia 3 lesions in the Atypical Squamous Cells of Undetermined Significance Low-Grade Squamous Intraepithelial Lesion Triage Study: implications for subject safety and lead-time bias. Cancer Epidemiol Biomarkers Prev. 2003;12(4):372-379.
46. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007; 121(3):621-632.
47. Stoler MH, Castle PE, Solomon D, et al. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007;127(3):335-337.
48. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124(3):516-520.
49. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072-1079.
50. Castle PE, Solomon D, Saslow D, et al. Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States. Cancer. 2008;113(10 suppl):3031-3035.
51. Pretorius RG, Kim RJ, Belinson JL, et al. Inflation of sensitivity of cervical cancer screening tests secondary to correlated error in colposcopy. J Low Genit Tract Dis. 2006;10(1):5-9.